March 19, 2021

Isofol receives recommendation from iDSMB to complete the AGENT study for market registration as planned with 440 patients

Link to the press release >>

November 2, 2020

Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

Link to the press release >>

See how arfolitixorin
works in cancer cells

See the animation >>

Previous

Next

Startpage 2

Upcoming Events

  • June 23, 2021 - June 23, 2021
    Annual General Meeting 2021
  • August 23, 2021 - August 23, 2021
    Interim Report Q2 2021
  • November 15, 2021 - November 15, 2021
    Interim Report Q3 2021
  • February 25, 2022 - February 25, 2022
    Interim Report Q4 2021